International mpox trial finds no clinical benefit from tecovirimat
Medical Xpress
March 2, 2026
An international, randomized, double-blind, placebo-controlled Phase III study—the largest of its kind for mpox—found that tecovirimat did not improve clinical outcomes for adults with clade II mpox compared with placebo, while demonstrating a similar safety profile. Results of the STOMP/A5418 trial, published in the New England Journal of Medicine, underscore both the urgent need for alternative therapeutics and the critical importance of randomized trials during public health emergencies.
Verticals
healthmedical
Originally published on Medical Xpress on 3/2/2026